ICER Releases Draft Evidence Report on CAR T-Cell Therapy for B-Cell Cancers
On December 19, the Institute for Clinical and Economic Review (ICER) released a Draft Evidence Report assessing the comparative clinical effectiveness and value of tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta). The draft report, along with draft voting questions, will be open to public comment for 4 weeks.
Findings contained in this report are preliminary and subject to change based on public comment and further analysis of the evidence.
Both drugs are chimeric antigen receptor (CAR) T-cell therapies and were approved earlier this year as potentially curative treatments for certain cancers. Tisagenlecleucel was approved for patients under age 25 with B-cell precursor acute lymphoblastic leukemia, and is also part of an ongoing study of adults with diffuse large B-cell lymphoma. Axicabtagene ciloleucel is indicated for adults with relapsed or refractory large B-cell non-Hodgkin lymphoma.
ICER is committed to engaging with all stakeholders in a thorough and transparent manner. Prior to conducting this review, ICER spoke with key patient groups and clinical experts, and accepted public comments on a Draft Scoping Document. The current draft report incorporates input received from patients, clinicians, and other stakeholders during each of these opportunities for engagement.
Submit a Public Comment
The Draft Evidence Report and Draft Voting Questions are now open to public comment until January 24, 2018 at 5 PM EST. All stakeholders are invited to submit formal comments by email to publiccomments@icer-review.org.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
